Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered advanced or metastatic triple-negative or HR-positive/HER2-negative breast cancer
CTR20182270Phase 3Suspended
- Sponsor
- Roche
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ipatasertib in triple-negative breast cancer (TNBC), breast cancer, sponsored by Roche. Started Feb 2018; status: suspended.
02
Drugs
ipatasertib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on CTR20182270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182270.